

Saskatchewan Immunization Manual Amendments June 2024

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 5 Immunization Schedules

- TOC first page – new section titles
 - PNEU-C-15 SCHEDULE FOR HEALTHY CHILDREN < 5 YEARS DELAYED BY 1 MONTH OR MORE
 - PNEU-C-20 SCHEDULE FOR MEDICALLY HIGH-RISK CHILDREN <5 YEARS DELAYED BY 1 MONTH OR MORE
- TOC second page – page numbers revised for section 4.5.2 onward.
- P. 1 Section 1.1 Routine Immunization Schedule for Infants, Children and Adolescents
 - Pneu-C-13 replaced with Pneu-C-15.
- P. 3 Section 1.3A Pneu-C-15 Vaccine Schedule for Healthy Children (<5 years old) Delayed by 1 Month or More
 - Section title updated.
- P. 4 Section 1.3B Pneu-C-20 Vaccine Schedule for Medically High-Risk Children (<5 years old) Delayed by 1 Month or More
 - Section retitled as these children require Pneu-C-20.
 - Two age presentation for children < 1 year old noted, and immunization requirements align with [CIG pneumococcal chapter](#).
 - **New** footnote #4: May be eligible to receive 1 dose of Pneu-C-20 if no doses are documented. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age
- P. 5 Section 1.4 Children 1 Year and Older but less than 7 Years Who Present for Immunizations
 - Pneu-C-13 replaced with Pneu-C-15.
 - Footnote #2 revised: Pneu-C-15 schedules for children <5 years old depend on age of child at presentation and previous doses received. Refer to 1.3A Pneumococcal Conjugate 15 Vaccine Schedule for Healthy Children (<5 years old) Delayed by 1 Month or More; or 1.3B Pneumococcal Conjugate 20 Vaccine Schedule for Medically High-Risk Children (<5 years old) Delayed by 1 Month or More.
- P. 6 Section 1.5 Children 7 to 17 Years Who Present for Immunizations
 - Removed from footnote 3: *Anyone born since January 1, 2003 is eligible to receive a cohort-based varicella vaccine series*, to simplify bullet as cohort has aged out.
- P. 7 Section 1.6 Adults 18 Years and Older Who Present for Immunizations
 - Pneu-P-23 replaced with Pneu-C-20 for individuals 65 years and older who have never received any previous pneumococcal vaccines.
- P. 8 Section 1.7 Recommended Publicly Funded Immunizations for Adults Who Completed a Primary Childhood Vaccine Series
 - Pneu-P-23 removed and replaced with Pneu-C-20.
 - Indications updated, and hyperlinks to [SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age](#) and [Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older](#) added.
- P. 9 Section 1.8 Publicly Funded Vaccine Eligibility Criteria
 - Pneu-C-15 added for healthy children < 5 years.
 - Pneu-P-23 removed and replaced with Pneu-C-20.
 - Indications updated, and hyperlinks to [SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age](#) and [Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older](#) added.
- P. 11 Section 2.1 Minimum intervals for specific vaccine series
 - Pneu-C-13 removed.

Saskatchewan Immunization Manual Amendments

June 2024

- Pneu-C-15 added with new footnote 7A: Refer to 1.3A Pneu-C-15 Vaccine Schedule for Healthy Children (<5 years old) Delayed by 1 Month or More.
- Pneu-C-20 added with new footnote 7B: Refer to 1.3B Pneu-C-20 Vaccine Schedule for Medically High-Risk Children (<5 years old) Delayed by 1 Month or More.
- Previous footnote 15 removed: Product monograph scheduling May 6, 2021.
- P. 19 Section 4.1 Unknown or Uncertain Immunization Status
 - Added to adults ≥18 years who were born or spent their childhood in Canada: Refer to Appendix 5.4: Publicly Funded Varicella Immunization Eligibility and Panorama Directives.
- P. 22 Section 4.5.1 Special Care Homes
 - Bullet c revised: Obtain an immunization history and immunize individuals according to SIM Chapter 5 schedules and Chapter 7, Immunization of Special Populations.
 - Bullets d to g removed.
- p. 22 Section 4.5.2 Personal Care Homes
 - Bullet a revised: Obtain an immunization history and immunize individuals according to SIM Chapter 5 schedules and Chapter 7, Immunization of Special Populations.
 - Bullets b and c removed.
- P. 31 Appendix 5.6: Immunization Recommendations for Children Presenting at 4-6 years of Age
 - “older’ children specified in first paragraph.

Chapter 7 Immunization of Special Populations

- P. 3 Section 1.4.1 Consideration for MMR and Varicella Immunization of Immunocompromised Individuals
 - Addition – MMRV is contraindicated.
- P. 5 Section 2.1A Publicly Funded Vaccines – Bleeding Disorders
 - LAIV bullet revised to align with CIG: Live attenuated influenza vaccine (LAIV) is contraindicated for children 2 to 17 years of age currently receiving aspirin or aspirin-containing therapy.
- P. 6 Section 2.2A Publicly Funded Vaccines Cardiac Disease
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
- P. 6 Section 2.3A Publicly Funded Vaccines – Cochlear Implant
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children and Men-C-C at 1 year old.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
 - Bullet addition to Men-C-ACYW-135 - Replace Men-C-C with Men-C-ACYW-135 at 12 months of age.
- P. 7 Section 2.4A Publicly Funded Vaccines – Asplenia
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children and Men-C-C at 1 year old.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.

Saskatchewan Immunization Manual Amendments

June 2024

- Bullet addition to Men-C-ACYW-135 - Replace Men-C-C with Men-C-ACYW-135 at 12 months of age.
- P. 8 Section 2.5A Publicly Funded Vaccines – CSF Disorders
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children and Men-C-C at 1 year old.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
 - Bullet addition to Men-C-ACYW-135 - Replace Men-C-C with Men-C-ACYW-135 at 12 months of age.
- P. 8 Sections 2.6A Publicly Funded Vaccines – CF and 2.7A Publicly Funded Vaccines – DM
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
- P. 9 Sections 2.8A Publicly Funded Vaccine – Liver Disease and 2.9A Publicly Funded Vaccines Lung Disease
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
- P. 10 Section 2.10A Publicly Funded Vaccines – Malignancies/Cancer (must have an Active Diagnosis)
 - Administer rotavirus vaccine and all routine **inactivated** vaccines **except Pneu-C-15 for children**.
 - Pneu-C-13 and Pneu-P-23 removed.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
 - **REMOVED as no longer applicable** - Please note that individuals who present as ‘cancer-free’ in the future do not qualify for additional vaccine doses (i.e., a second dose of Pneu-P-23) as their risk is the same as everyone else.
- P. 11 Section 2.11A Publicly Funded Vaccines – Those with a Neurological Conditions that Impeded the Clearance of the Respiratory/Oral Secretions
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
- P. 12 Section 2.12A Publicly Funded Vaccines – Renal Disease
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
- P. 13 Section 2.13A Publicly Funded Vaccines – Sickle Cell Disease
 - Pneu-C-13 and Pneu-P-23 removed.

Saskatchewan Immunization Manual Amendments

June 2024

- Routine vaccines to be administered except for Pneu-C-15 for children and Men-C-C at 1 year old.
- Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
- Bullet additions to Men-C-ACYW-135 - Replace Men-C-C with Men-C-ACYW-135 at 12 months of age. Eligible for 1 reinforcement dose every 5 years (after the last dose in the primary series).
- P. 14 3.1A Publicly Funded Vaccines - Congenital Immunodeficiency and 3.2A: Publicly Funded Vaccines - Acquired Complement Deficiency
 - Pneu-C-13 and Pneu-P-23 removed.
 - Routine vaccines to be administered except for Pneu-C-15 for children and Men-C-C at 1 year old.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
 - Bullet additions to Men-C-ACYW-135 - Replace Men-C-C with Men-C-ACYW-135 at 12 months of age. Eligible for 1 reinforcement dose every 5 years (after the last dose in the primary series).
- P. 15 Section 3.3 HIV
 - Under Live Attenuated Viral or Bacterial Vaccine, intravenous immunoglobulin abbreviation corrected in last bullet.
- P. 16 Section 3.3A Publicly Funded Vaccines and Immune Globulins – Human Immunodeficiency Virus
 - Administer rotavirus vaccine and all routine **inactivated** vaccines **except Pneu-C-15 for children**.
 - Pneu-C-13 and Pneu-P-23 removed.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
 - Bullet additions to Men-C-ACYW-135 - Replace Men-C-C with Men-C-ACYW-135 at 12 months of age. Eligible for 1 reinforcement dose every 5 years (after the last dose in the primary series) [Reminder that this does only applies to adults who started the series before 18 year old].
 - New vaccine contraindications added – MMRV and LAIV.
- P.19 Medical Treatment
 - Added: The third dose of a pneumococcal conjugate vaccine that forecasts at 6 months of age is unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.
 - Removed: The third dose of Pneu-C-13 vaccine that forecasts at 6 months of age is unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.
- P. 20 3.7A Publicly Funded Vaccines - Medical Treatment
 - Administer all routine **inactivated** vaccines **except Pneu-C-15 for children**.
 - Pneu-C-13 and Pneu-P-23 removed.
 - Pneu-C-20 to be administered. Refer to SIM CH. 10 Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age and Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older for guidance.
 - Addition – Rotavirus – Consult with infant’s specialist.
- P. 21 Section 4.0 Post-Exposure

Saskatchewan Immunization Manual Amendments June 2024

- Original second sentence removed: Without intervention, this risk is estimated to be 90% if the mother is HBsAg positive and 5-20% if the mother is HBsAg negative.
- P. 22 Section 5.2.1.1 Inactivated Vaccines [Pregnancy]
 - Inactivated influenza vaccine and COVID-19 vaccines are recommended.
 - There are no data to indicate that currently approved inactivate vaccines are teratogenic or embryotoxic, or have resulted in specific adverse pregnancy outcomes. However, a risk/benefit discussion with the client is encouraged and their potential for exposure should be considered (e.g., travel to high-risk country for polio, exposure to meningitis, or their partner is an IV drug user (HB)).

- P. 23 Section A 5.2.A: Publicly Funded Vaccines – Pregnancy

All inactivated routine vaccines except HPV vaccines	<ul style="list-style-type: none"> ● Inactivated influenza vaccine and COVID-19 vaccines are recommended. ● There are no data to indicate that currently approved inactivated vaccines are teratogenic or embryotoxic, or have resulted in specific adverse pregnancy outcomes. However, a risk/benefit discussion with the client is encouraged and their current medical risk factors and potential for disease exposure should be considered (e.g., travel to high-risk country for polio, exposure to meningitis, or their partner is an IV drug user (HB)).
HPV (any)	Contraindicated during pregnancy.

- P. 28 Section 7.1 Premature Birth
 - Third paragraph amended to state: Premature infants and other children at risk of contracting respiratory syncytial virus (RSV) may be eligible to receive an RSV-specific monoclonal antibody (i.e., palivizumab or nirsevimab). These do not interfere with the immune response of vaccines (refer to SIM, Chapter 5, Immunization Schedules, Section 3.5, Spacing of Live Vaccines, Blood Products and Immune Globulin Preparations. A provincial RSV program exists to coordinate this service outside of public health <https://momsandkidsask.saskhealthauthority.ca/infant-child-health/specialty-care/respiratory-syncytial-virus-program>.
- P. 28 Section 7.2 Individuals Recently New to Canada
 - Last two hyperlink corrected.
- P. 33 Appendix 7.1: Publicly Funded Vaccine Recommendations for Specific Populations by Panorama Risk Factor Category
 - **This table has numerous revisions to content and footnoted and must be reviewed by all staff.**
 - Pneu-C-13 and Pneu-P-23 removed from table.
 - Pneu-C-20 added.
 - Footnotes amended on Page 36.
- P. 41 Appendix 7.6: Publicly Funded Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant Recipients
 - **This table has numerous revisions to content and footnoted and must be reviewed by all staff.**
 - Strains removed from COVID-19 vaccine.
 - High dose HB vaccine specified.
 - Pneu-C-13 and Pneu-P-23 removed from table.
 - Pneu-C-20 added. Individuals who commenced a Pneu-C-13 series must complete their series with Pneu-C-20. Individuals who completed a prior Pneu-C-13 series and/or received Pneu-P-23 dose(s) should receive 1 Pneu-C-20 dose when: it has been a) ≥ 1 year after last documented Pneu-P-23; AND b) ≥ 8 weeks from last documented Pneu-C-13 dose, as applicable.

Saskatchewan Immunization Manual Amendments

June 2024

- P. 44 Appendix 7.9: Publicly Funded Immunization Schedule for Adult Solid Organ Pre-Transplant Candidates
 - This table has numerous revisions to content and footnoted and must be reviewed by all staff.
 - Strains removed from COVID-19 vaccine.
 - High dose HB vaccine specified.
 - Pneu-C-13 and Pneu-P-23 removed from table.
 - Pneu-C-20 added. Individuals who received a prior Pneu-C-13 dose and/or Pneu-P-23 dose(s) should receive 1 Pneu-C-20 dose pre-transplant when: it has been a) ≥ 1 year after last documented Pneu-P-23; AND b) ≥ 8 weeks from last documented Pneu-C-13 dose, as applicable. Ineligible for Pneu-C-20 if they previously received Pneu-C-15 AND Pneu-P-23.
 - DTaP-IPV-Hib may be administered off label to all transplant candidates (whose age is beyond the vaccine's licensed age range) to reduce the number of injections they require to meet the antigen requirements as noted in this schedule.
- P. 45 Appendix 7.10: Publicly Funded Immunization Schedule for Adult Solid Organ Post-Transplant Recipients
 - This table has numerous revisions to content and footnoted and must be reviewed by all staff.
 - Strains removed from COVID-19 vaccine.
 - High dose HB vaccine specified.
 - Men-C-ACYW-135 reinforcement dose every 5 years.
 - Pneu-C-13 and Pneu-P-23 removed from table.
 - Pneu-C-20 added. Individuals who received a prior Pneu-C-13 dose and/or a Pneu-P-23 dose should receive 1 Pneu-C-20 post-transplant (if not received pre-transplant) dose when: it has been a) ≥ 1 year after last documented Pneu-P-23; AND b) ≥ 8 weeks from last documented Pneu-C-13 dose, as applicable. Ineligible for Pneu-C-20 if they previously received Pneu-C-15 AND Pneu-P-23.

Chapter 10 Biological Products

- TOC second page under
 - Pevnar 20
 - Age-based Risk Factor Eligibility for Pneu-C-20 Immunization (as noted in Panorama)
 - Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age
 - Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older
 - Deleted under Pneu-P-23
 - Pneu-P-23 recommendations for adults 18+ immunized with only Pneu-C-15 or Pneu-C-20
- DTaP-IPV-Hib vaccines (Infanrix-IPV/Hib, Pediacel and Pentacel)
 - Footnote 2 revised: If a child's immunization schedule is delayed, the child may require fewer doses of Hib vaccine. Refer to SIM, Chapter 5, Immunization Schedules Section 1.2, Hib Schedule for Children Delayed by 1 Month or More.
 - Footnote 5 revised: May be administered off label to HSCT and solid organ transplant patients (whose age is beyond the vaccine's licensed age range) to reduce the number of injections they require to meet the antigen requirements as noted in SIM chapter 7 Appendix 7.6, 7.9 or 7.10 immunization schedules.
- Gardasil 9 – Pregnancy added as a contraindication.
- MMR II - MMR II may be given IM as per the product monograph, but SC recommended for practice consistency.
- BEXSERO (Men-B4C)

Saskatchewan Immunization Manual Amendments

June 2024

- The product monograph indicates 2 schedules for infants younger starting a series before 6 months of age. **AS THIS VACCINE IS FOR HIGH-RISK INFANTS, PLEASE ADMINISTER THE 4-DOSE SCHEDULE TO THOSE <6 MONTHS OF AGE.**
- PREVNAR 13 and Pneumovax 23 updated to non-publicly funded vaccines.
- VAXNEUVANCE Pneu-C-15
 - **STAFF MUST REVIEW THIS PAGE AND FOOTNOTES.**
 - Updated to publicly funded vaccine for children who do not have any medical or lifestyle risk factors and who present when younger than 5 years old.
- PREVNAR 20 (4 pages)
 - **STAFF MUST REVIEW ALL PAGES AND FOOTNOTES.**
 - Page 1 – Updated with publicly funded indications:
 1. Adults 65 years and older who have never received any previous pneumococcal vaccines.
 2. Long-term care, personal care home and group home residents (all ages).
 3. Individuals 2 months through 64 years of age and select adults 65 years and older who have risk factors for pneumococcal disease. Refer to Age-based Risk Factor Eligibility for Pneu-C-20 Immunization (as noted in Panorama) as eligibility is based on age, approved risk factor, pneumococcal immunization history and interval after last pneumococcal vaccine dose.

NOTE: This vaccine is not publicly funded for individuals who do not have approved risk factors.
 - Page 2 - Age-based Risk Factor Eligibility for Pneu-C-20 Immunization (as noted in Panorama)
 - Ages are highlighted and risk factors vary by age at presentation.
 - Page 3 - Pneu-C-20 Immunization Flow Chart for Individuals Through 64 Years of Age
 - 'Risk factor' is the assessment starting point for this population.
 - Ineligible if previously received Pneu-C-20 dose **or** Pneu-P-23 & Pneu-C-15 vaccines.
 - Page 4 - Pneu-C-20 Immunization Flow Chart for Individuals 65 Years and Older
 - 'Immunization history' is the assessment starting point for this population.
 - Ineligible if previously received Pneu-C-20 dose **or** Pneu-P-23 & Pneu-C-15.
- ADACEL and BOOSTRIX
 - Indication **removed** as Tdap routine for all adults: Special Populations - Refer to Chapter 7, Immunization of Special Populations for specific medical condition.